Cargando…

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis

INTRODUCTION: This meta-analysis compares the effectiveness and safety of tumor necrosis factor α (TNF-α) antibodies (infliximab, adalimumab and certolizumab) with either a placebo or each of them in the treatment of Crohn's disease (CD). MATERIAL AND METHODS: A systematic review of literature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawalec, Paweł, Mikrut, Alicja, Wiśniewska, Natalia, Pilc, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2013
Materias:	Meta-analysis/Systematic review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832823/ https://www.ncbi.nlm.nih.gov/pubmed/24273556 http://dx.doi.org/10.5114/aoms.2013.38670

Ejemplares similares

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis
por: Moćko, Paweł, et al.
Publicado: (2016)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Kawalec, Paweł, et al.
Publicado: (2014)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2012)

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2018)

Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review
por: Kawalec, Paweł
Publicado: (2016)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kawalec, Paweł, et al.
Publicado: (2013)

Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα)
por: Cao, Brent L, et al.
Publicado: (2018)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet’s disease: a systematic review and meta-analysis
por: Mohammed, Reem Hamdy A, et al.
Publicado: (2023)

Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials
por: Kryst, Joanna, et al.
Publicado: (2020)

Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: Yang, Seungwon, et al.
Publicado: (2021)

The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis
por: Zhao, Heng-Nan, et al.
Publicado: (2021)

Association between tumor necrosis factor-α and chronic obstructive pulmonary disease: a systematic review and meta-analysis
por: Yao, Yang, et al.
Publicado: (2019)

Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
por: Holko, Przemysław, et al.
Publicado: (2018)

Tumor necrosis factor-α −308 G/A polymorphism and risk of sepsis, septic shock, and mortality: an updated meta-analysis
por: Wang, Hao, et al.
Publicado: (2017)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Health-Related Quality of Life Impairment and Indirect Cost of Crohn’s Disease: A Self-Report Study in Poland
por: Holko, Przemysław, et al.
Publicado: (2016)

Stricturing Crohn's disease: what is the role of endoscopic stenting? A systematic review
por: Scotti, Giorgia Burrelli, et al.
Publicado: (2023)

Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn’s disease: a meta-analysis
por: Yu, Yu, et al.
Publicado: (2019)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Protective association of TNFSF15 polymorphisms with Crohn's disease and ulcerative colitis: A meta-analysis
por: He, Liwen, et al.
Publicado: (2018)

Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis
por: Migliore, Alberto, et al.
Publicado: (2021)

Polymorphism rs6478109 in the TNFSF15 gene contributes to the susceptibility to Crohn’s disease but not ulcerative colitis: a meta-analysis
por: Zhou, Yuan, et al.
Publicado: (2020)

Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn’s disease
por: Attauabi, Mohamed, et al.
Publicado: (2021)

ABCB1 Gene Polymorphisms and Glucocorticoid-Induced Avascular Necrosis of the Femoral Head Susceptibility: A Meta-Analysis
por: Li, Zhigang, et al.
Publicado: (2014)

The Diagnostic Value of Polymerase Chain Reaction for Mycobacterium tuberculosis to Distinguish Intestinal Tuberculosis from Crohn's Disease: A Meta-analysis
por: Jin, Ting, et al.
Publicado: (2017)

Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
por: Kim, Eun Sil, et al.
Publicado: (2023)

Efficacy of early biologic therapy versus late/conventional therapy in children and adolescents with Crohn’s disease: A systematic review and meta-analysis
por: Zhang, Lei, et al.
Publicado: (2023)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Hip survival rate in the patients with avascular necrosis of femoral head after transtrochanteric rotational osteotomy: a systematic review and meta-analysis
por: Xu, Ying-Xing, et al.
Publicado: (2019)

A Comparison of Endoscopic Versus Surgical Creation of a Cystogastrostomy to Drain Pancreatic Pseudocysts and Walled-Off Pancreatic Necrosis in 5500 Patients
por: Suggs, Patrick, et al.
Publicado: (2020)

Microbiota signatures and mucosal healing in the use of enteral nutrition therapy v. corticosteroids for the treatment of children with Crohn’s disease: a systematic review and meta-analysis
por: Ding, Zhaolu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_22iv5cib02dftal0n33ctpm1rf